MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/meg.0b013e328362dc99

Медицинская библиотека · European journal of gastroenterology & hepatology · 2014

Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.

Giordanino Chiara, Sacco Marco, Ceretto Simone, Smedile Antonina, Ciancio Alessia, Cariti Giuseppe, De Blasi Tiziano, Picciotto Antonio, Marenco Simona, Grasso Alessandro, Pirisi Mario, Smirne Carlo, Colletta Cosimo, Traverso Antonio, Mazzucco Dario, Ciccone Giovannino, Simondi Daniele, Rizzetto Mario, Saracco Giorgio

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

To evaluate whether, in chronic hepatitis C-positive naive patients recruited in the routine clinical setting and treated with pegylated-interferon-α2b (Peg-IFN) and ribavirin (RBV), the sustained virologic response (SVR) is durable over the long term and whether it is associated with a decrease in liver complications and incidence of glucose abnormalities.

PATIENTS AND

METHODS

This was a prospective long-term follow-up study of 182 naive patients enrolled in 2001-2002 and treated with Peg-IFN and RBV and followed up to December 2010, with clinical, biochemical, and virological evaluations every 6-12 months.

RESULTS

None of the 115 (63.2%) sustained responders showed late viremic relapse during the follow-up. SVR was better defined at 24 weeks (16/16 relapsers, 100%) than at 12 weeks after the end of therapy (14/16 relapsers, 87.5%). On multivariable analysis, viral genotype (odds ratio 0.16, 95% confidence interval 0.07-0.36, P=0.0001) and a greater than 20% RBV reduction (odds ratio 5.21, 95% confidence interval 1.54-17.67, P=0.008) predicted long-term response (LTR) independently. The incidence of cirrhosis was significantly higher among nonresponders (21.3%) compared with long-term responders (0.9%, P≤0.0001), but the risk of developing glucose abnormalities was not significantly reduced in long-term responders (hazard ratio 1.36, P=0.363). Hepatocellular carcinoma occurred only in three cases.

CONCLUSION

SVR achieved in patients treated in the routine clinical setting with Peg-IFN and RBV is durable over the long term and LTR significantly reduces the risk of progression to cirrhosis; however, in a population with mild liver fibrosis, the clinical impact of LTR on the risk of glucose abnormalities seems negligible.

Для цитирования: Giordanino Chiara, Sacco Marco, Ceretto Simone, Smedile Antonina, Ciancio Alessia, Cariti Giuseppe, De Blasi Tiziano, Picciotto Antonio, Marenco Simona, Grasso Alessandro, Pirisi Mario, Smirne Carlo, Colletta Cosimo, Traverso Antonio, Mazzucco Dario, Ciccone Giovannino, Simondi Daniele, Rizzetto Mario, Saracco Giorgio. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.. European journal of gastroenterology & hepatology. 2014. DOI: 10.1097/meg.0b013e328362dc99.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.